So
Sorriso Pharma
Shanghai CNFounded 202050 employees
Private CapbiotechPrivateMetabolic
Platform: Oral GLP-1
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Talazanubrutinib | SOR-7863 | Phase 1/2 | 1 | EGFR | Wet AMDFSGS | ||
| Gozefutibatinib | SOR-128 | NDA/BLA | 2 | WRN | RASCD | ||
| Riboinavolisib | SOR-6580 | Phase 1/2 | 1 | CGRP | DMD |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (4)